Defunct Company
Total Trials
24
As Lead Sponsor
18
As Collaborator
6
Total Enrollment
2,716
NCT00089804
Study of LJP 394 in Lupus Patients With History of Renal Disease
Phase: Phase 3
Role: Lead Sponsor
Start: Oct 31, 2004
Completion: Feb 28, 2009
NCT00390091
Study of LJP 394 (Abetimus Sodium) in Lupus Patients
Phase: Phase 2
Start: Sep 30, 2006
Completion: Not specified
NCT00514696
Study of the Safety of GCS-100 in Subjects With Chronic Lymphocytic Leukemia
Start: Feb 28, 2007
Completion: Apr 30, 2009
NCT00609817
Safety and Efficacy Study of GCS-100LE in the Treatment of Multiple Myeloma
Phase: Phase 1
Start: May 31, 2008
NCT00776802
GCS-100LE in Combination With Etoposide and Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Phase: Phase 1/2
Start: Jul 31, 2008
NCT01717248
Safety Study of GCS-100 to Treat Chronic Kidney Disease
Start: Jan 31, 2013
Completion: Jun 30, 2013
NCT01843790
A Phase 2a Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease
Start: Jun 30, 2013
Completion: Sep 30, 2014
NCT02155673
A Phase 2 Extension Study of Study GCS-100-CS-4002
Start: Jan 31, 2014
Completion: Jun 30, 2016
NCT01906307
A Phase 1 Study of LJPC-501 in Patients With Hepatorenal Syndrome
Start: Mar 31, 2014
Completion: Dec 31, 2015
NCT02333955
A Phase 2 Extension of Study GCS-100-CS-4003
Start: Jan 31, 2015
Completion: Jul 31, 2016
NCT02312050
A Phase 2b Study of GCS-100 in Patients With Chronic Kidney Disease Caused by Diabetes
Start: Mar 31, 2015
Completion: Dec 31, 2016
NCT02338843
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
Completion: Feb 18, 2017
NCT03395704
A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis
Start: Nov 29, 2017
Completion: Oct 28, 2019
NCT03381833
A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Patients With Transfusion-Dependent Beta Thalassemia
Start: Nov 30, 2017
Completion: Jan 14, 2020
NCT03431077
A Study of LJPC-501 in Pediatric Patients With Hypotension
Start: Feb 11, 2018
Completion: Apr 14, 2018
NCT03623529
A Study of LJPC-501 in Paediatric Patients With Hypotension Associated With Distributive or Vasodilatory Shock
Start: Aug 31, 2018
Completion: Apr 30, 2023
NCT04529005
Angiotensin II in the Perioperative Management of Hypotension in Kidney Transplant Recipients
Phase: Phase 4
Role: Collaborator
Start: Aug 13, 2020
Completion: Aug 1, 2021
NCT05193370
Angiotensin II vs. Vasopressin in Septic Shock
Start: Jan 3, 2022
Completion: Nov 30, 2022
NCT04904562
Angiotensin II for Distributive Shock
Start: Jun 1, 2022
Completion: Dec 31, 2024
NCT04901169
Angiotensin II in Liver Transplantation
Phase: Phase 2/3
Start: Jun 28, 2022
Completion: Sep 1, 2026
NCT05824767
Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock
Start: Apr 17, 2023
Completion: Mar 12, 2025
NCT06122987
Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock
Start: Dec 4, 2023
Completion: Jan 31, 2025